pamidronate has been researched along with Cerebral Palsy in 11 studies
Cerebral Palsy: A heterogeneous group of nonprogressive motor disorders caused by chronic brain injuries that originate in the prenatal period, perinatal period, or first few years of life. The four major subtypes are spastic, athetoid, ataxic, and mixed cerebral palsy, with spastic forms being the most common. The motor disorder may range from difficulties with fine motor control to severe spasticity (see MUSCLE SPASTICITY) in all limbs. Spastic diplegia (Little disease) is the most common subtype, and is characterized by spasticity that is more prominent in the legs than in the arms. Pathologically, this condition may be associated with LEUKOMALACIA, PERIVENTRICULAR. (From Dev Med Child Neurol 1998 Aug;40(8):520-7)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to test the efficacy of low doses of pamidronate in increasing bone mineral density (BMD) in non-ambulatory children and adolescents with cerebral palsy (CP)." | 9.12 | Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study. ( Bruzoni, M; Coughlin, S; Heldt, K; Kreikemeier, R; Lerner, G; Plotkin, H, 2006) |
| "5) nonambulatory children with cerebral palsy or a neuromuscular disorder received cyclic intravenous administration of pamidronate." | 9.11 | Cyclic administration of pamidronate to treat osteoporosis in children with cerebral palsy or a neuromuscular disorder: a clinical study. ( Allington, N; Gerard, P; Vivegnis, D, 2005) |
| "Some children with cerebral palsy (CP) have frequent fractures due to low bone mineral density and receive treatment with pamidronate, an intravenous bisphosphonate." | 7.83 | Pamidronate Treatment to Prevent Reoccurring Fractures in Children With Cerebral Palsy. ( Bachrach, S; Dabney, K; Holmes, L; Kecskemethy, HH; Miller, F; Rogers, KJ; Sees, JP; Sitoula, P, 2016) |
| "The aim of this study was to assess the rate of fracture before and after a 1-year course of intravenous pamidronate in children with spastic quadriplegic cerebral palsy (CP) who had previously experienced fractures." | 7.76 | Decreased fracture incidence after 1 year of pamidronate treatment in children with spastic quadriplegic cerebral palsy. ( Bachrach, SJ; Harcke, HT; Hossain, J; Kecskemethy, HH, 2010) |
| "The aim of this study was to test the efficacy of low doses of pamidronate in increasing bone mineral density (BMD) in non-ambulatory children and adolescents with cerebral palsy (CP)." | 5.12 | Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study. ( Bruzoni, M; Coughlin, S; Heldt, K; Kreikemeier, R; Lerner, G; Plotkin, H, 2006) |
| "5) nonambulatory children with cerebral palsy or a neuromuscular disorder received cyclic intravenous administration of pamidronate." | 5.11 | Cyclic administration of pamidronate to treat osteoporosis in children with cerebral palsy or a neuromuscular disorder: a clinical study. ( Allington, N; Gerard, P; Vivegnis, D, 2005) |
| "To evaluate in a double-blind, placebo-controlled clinical trial the safety and efficacy of intravenous pamidronate to treat osteopenia in nonambulatory children with cerebral palsy." | 5.10 | Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. ( Bachrach, SJ; Harcke, HT; Henderson, RC; Kecskemethy, HH; Lark, RK; Miller, F, 2002) |
| "Some children with cerebral palsy (CP) have frequent fractures due to low bone mineral density and receive treatment with pamidronate, an intravenous bisphosphonate." | 3.83 | Pamidronate Treatment to Prevent Reoccurring Fractures in Children With Cerebral Palsy. ( Bachrach, S; Dabney, K; Holmes, L; Kecskemethy, HH; Miller, F; Rogers, KJ; Sees, JP; Sitoula, P, 2016) |
| "In the nonambulatory cerebral palsy (CP) population with a prior history of fracture, the use of pamidronate is not always effective in preventing further fractures." | 3.78 | Fracture after bisphosphonate treatment in children with cerebral palsy: the role of stress risers. ( Bachrach, SJ; Grissom, LE; Harcke, HT; Kecskemethy, HH; Stevenson, KL, 2012) |
| "Thirty-four children with cerebral palsy and severe osteoporosis were treated for approximately 1 yr with pamidronate (three times per year)." | 3.76 | Risk of corrected QT interval prolongation after pamidronate infusion in children. ( Bougnères, P; Linglart, A; Marchand, I; Rothenbuhler, A, 2010) |
| "The aim of this study was to assess the rate of fracture before and after a 1-year course of intravenous pamidronate in children with spastic quadriplegic cerebral palsy (CP) who had previously experienced fractures." | 3.76 | Decreased fracture incidence after 1 year of pamidronate treatment in children with spastic quadriplegic cerebral palsy. ( Bachrach, SJ; Harcke, HT; Hossain, J; Kecskemethy, HH, 2010) |
| "To determine the effect of intravenous pamidronate on the bone mineral density of children with osteogenesis imperfecta and spastic quadriplegic cerebral palsy." | 3.73 | Bone densitometry in pediatric patients treated with pamidronate. ( Bachrach, SJ; Grissom, LE; Harcke, HT; Kecskemethy, HH; McKay, C, 2005) |
| "In recent years, bisphosphonates, primarily intravenous (iv) pamidronate, have become very widely used in children with severe osteogenesis imperfecta (OI)." | 3.73 | Low doses of pamidronate for the treatment of osteopenia in non-ambulatory children. ( Henderson, R, 2006) |
| "Pain is one of the most common symptoms in children and young people (CYP) with life-limiting conditions (LLCs) which include a wide range of diagnoses including cancer." | 2.52 | Pharmacological interventions for pain in children and adolescents with life-limiting conditions. ( Beecham, E; Bluebond-Langner, M; Candy, B; Howard, R; Jones, L; Laddie, J; McCulloch, R; Rees, H; Vickerstaff, V, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sees, JP | 1 |
| Sitoula, P | 1 |
| Dabney, K | 1 |
| Holmes, L | 1 |
| Rogers, KJ | 1 |
| Kecskemethy, HH | 5 |
| Bachrach, S | 1 |
| Miller, F | 2 |
| Beecham, E | 1 |
| Candy, B | 1 |
| Howard, R | 1 |
| McCulloch, R | 1 |
| Laddie, J | 1 |
| Rees, H | 1 |
| Vickerstaff, V | 1 |
| Bluebond-Langner, M | 1 |
| Jones, L | 1 |
| Rothenbuhler, A | 1 |
| Marchand, I | 1 |
| Bougnères, P | 1 |
| Linglart, A | 1 |
| Bachrach, SJ | 4 |
| Harcke, HT | 5 |
| Hossain, J | 1 |
| Stevenson, KL | 1 |
| Grissom, LE | 3 |
| Henderson, RC | 1 |
| Lark, RK | 1 |
| McKay, C | 1 |
| Allington, N | 1 |
| Vivegnis, D | 1 |
| Gerard, P | 1 |
| Henderson, R | 1 |
| Plotkin, H | 1 |
| Coughlin, S | 1 |
| Kreikemeier, R | 1 |
| Heldt, K | 1 |
| Bruzoni, M | 1 |
| Lerner, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation[NCT02074631] | Phase 2 | 80 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for pamidronate and Cerebral Palsy
| Article | Year |
|---|---|
Pharmacological interventions for pain in children and adolescents with life-limiting conditions.
Topics: Adolescent; Alendronate; Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Child; Child, Preschool | 2015 |
3 trials available for pamidronate and Cerebral Palsy
| Article | Year |
|---|---|
Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial.
Topics: Adolescent; Bone Diseases, Metabolic; Cerebral Palsy; Child; Diphosphonates; Double-Blind Method; Fe | 2002 |
Cyclic administration of pamidronate to treat osteoporosis in children with cerebral palsy or a neuromuscular disorder: a clinical study.
Topics: Adolescent; Anti-Inflammatory Agents; Cerebral Palsy; Child; Child, Preschool; Diphosphonates; Drug | 2005 |
Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study.
Topics: Adolescent; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Cerebral Palsy | 2006 |
7 other studies available for pamidronate and Cerebral Palsy
| Article | Year |
|---|---|
Pamidronate Treatment to Prevent Reoccurring Fractures in Children With Cerebral Palsy.
Topics: Adolescent; Bone Density Conservation Agents; Cerebral Palsy; Child; Child, Preschool; Diphosphonate | 2016 |
Risk of corrected QT interval prolongation after pamidronate infusion in children.
Topics: Adolescent; Arrhythmias, Cardiac; Cerebral Palsy; Child; Diphosphonates; Electrocardiography; Female | 2010 |
Decreased fracture incidence after 1 year of pamidronate treatment in children with spastic quadriplegic cerebral palsy.
Topics: Adolescent; Age Factors; Bone Density; Bone Density Conservation Agents; Cerebral Palsy; Child; Chil | 2010 |
Fracture after bisphosphonate treatment in children with cerebral palsy: the role of stress risers.
Topics: Adolescent; Bone Density Conservation Agents; Cerebral Palsy; Child; Child, Preschool; Diphosphonate | 2012 |
Radiographic features of bisphosphonate therapy in pediatric patients.
Topics: Adolescent; Bone and Bones; Bone Density; Bone Development; Bone Diseases, Metabolic; Cerebral Palsy | 2003 |
Bone densitometry in pediatric patients treated with pamidronate.
Topics: Absorptiometry, Photon; Adolescent; Adult; Bone Density; Cerebral Palsy; Child; Child, Preschool; Di | 2005 |
Low doses of pamidronate for the treatment of osteopenia in non-ambulatory children.
Topics: Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Cerebral Palsy; Child; Chi | 2006 |